Table 2. CAR clinical trials by target antigen.
Antigen | Signaling and accessory |
Cell typea |
Delivery methodb |
Disease(s) | Primary institution(s) |
Phase(s) | Enrollment | NCT #c |
---|---|---|---|---|---|---|---|---|
BCMA | 41BBz | T cells | NA | MM | UPenn | Phase 0 | 30 | NCT02546167 |
BCMA | 41BBz | T cells | Lenti | MM | bluebird bio | Phase 1 | 50 | NCT02658929 |
BCMA | 41BBz | T cells | Lenti | MM | bluebird bio | 50 | NCT02786511 | |
CD7 | CD28-41BBz | NK-92 | NA | AML | PersonGen | Phase1,2 | 10 | NCT02742727 |
CD19 | 41BBz | T cells | Retro | B-ALL, B-CLL, B-NHL | UPenn | 110 | NCT01029366 | |
CD19 | 41BBz | T cells (allo) | Lenti | B-ALL | UPenn | Phase 1 | 10 | NCT01551043 |
CD19 | 41BBz | T cells | Lenti | B-ALL, B-CLL, B-NHL | UPenn | Phase 1 | 20 | NCT01626495 |
CD19 | 41BBz | T cells | Lenti | B-CLL, B-SLL | UPenn | Phase 2 | 65 | NCT01747486 |
CD19 | 41BBz | T cells 1:1 CD4+ and CD8+ | Lenti | B-ALL | Seattle Children's | Phase1,2 | 80 | NCT02028455 |
CD19 | 41BBz | T cells | Lenti | B-NHL | UPenn | Phase 2 | 51 | NCT02030834 |
CD19 | 41BBz | T cells | Lenti | B-ALL | UPenn | Phase 2 | 24 | NCT02030847 |
CD19 | 41BBz | T cells | RNA (electro) | HL | UPenn | Phase 0 | 16 | NCT02277522 |
CD19 | 41BBz | T cells | Lenti | B-NHL | Novartis | Phase 2 | 100 | NCT02445248 |
CD19 | 41BBz | T cells | RNA (electro) | HL | UPenn|CHOP | Phase 0 | 10 | NCT02624258 |
CD19 | 41BBz | T cells | Lenti | B-CLL, B-SLL | UPenn | 15 | NCT02640209 | |
CD19 | 41BBz | T cells | Lenti | B-NHL | UPenn | Phase1,2 | 12 | NCT02650999 |
CD19 | 41BBz | T cells | Lenti | B-CLL | Shanghai GeneChem | Phase1,2 | 30 | NCT02672501 |
CD19 | 41BBz | T cells | Lenti | MM | UPenn | Phase 2 | 25 | NCT02794246 |
CD19 | 41BBz and zeta-only | T cells | Retro | B-ALL, B-CLL, B-NHL | Chinese PLAGH | 12 | NCT01864889 | |
CD19 | 41BBz and zeta- only | T cells | Retro | B-NHL | Chinese PLAGH | Phase1,2 | 2 | NCT02081937 |
CD19 | 41BBz,CD20/34t | T cells (allo, gen mod) | Lenti | B-ALL, B-CLL, B-NHL | Servier | 200 | NCT02735083 | |
CD19 | 41BBz,CD20/34t | T cells (allo, gen mod) | Lenti | B-ALL, B-CLL | Servier | Phase 1 | 12 | NCT02746952 |
CD19 | 41BBz,EGFRt | T cells | Lenti | B-ALL, B-CLL, B-NHL | FHCRC|NCI | Phase1,2 | 145 | NCT01865617 |
CD19 | 41BBz,EGFRt | T cells | Lenti | B-NHL | Juno | Phase 1 | 70 | NCT02631044 |
CD19 | 41BBz,EGFRt | T cells | Lenti | B-NHL | FHCRC|NCI|Juno MedImmune AstraZeneca | Phase 1 | 42 | NCT02706405 |
CD19 | CD27z,iCasp9 | T cells | Lenti | B-NHL | PKU|UF | Phase1,2 | 20 | NCT02247609 |
CD19 | CD28-41BBz | T cells | Retro | B-CLL, B-NHL | Uppsala Univ. | Phase1,2 | 15 | NCT02132624 |
CD19 | CD28-41BBz,EGFRt | CMV or EBV Tcm cells (allo) | NA | B-ALL, B-CLL, B-NHL | FHCRC\\NCI | Phase1,2 | 1 | NCT01475058 |
CD19 | CD28z | T cells | Retro | B-NHL | NCI\NIHCC | Phase 1 | 43 | NCT00924326 |
CD19 | CD28z | T cells | NA | B-ALL | MSKCC | Phase 1 | 60 | NCT01044069 |
CD19 | CD28z | T cells (allo) | Virus | B-ALL, B-CLL, B cell lymphomas | NCI\NIHCC | Phase 1 | 42 | NCT01087294 |
CD19 | CD28z | T Cells | Transpos (electro) | B-NHL | M.D. Anderson Intrexon|Ziopharm | Phase 1 | 60 | NCT00968760 |
CD19 | CD28z | EBV-CTLs (allo) | NA | B-ALL, B-NHL | MSKCC | Phase 1 | 12 | NCT01430390 |
CD19 | CD28z | T Cells (allo) | Transposon (electro) | B-ALL, B-CLL, B-NHL | M.D. Anderson Intrexon|Ziopharm | Phase 1 | 140 | NCT01497184 |
CD19 | CD28z | T cells | Retro | B-ALL, B-NHL | NCI\NIHCC | Phase 1 | 52 | NCT01593696 |
CD19 | CD28z | T cells | NA | B-ALL, B-CLL, B-NHL | M.D. Anderson ZiopharmIIntrexon | Phase 1 | 30 | NCT02529813 |
CD19 | CD28z | T cells | NA | B-NHL | MSKCC | Phase 1 | 17 | NCT01840566 |
CD19 | CD28z | T cells | NA | B-ALL | MSKCC|Dana-Farber | Phase 1 | 24 | NCT01860937 |
CD19 | CD28z | T cells (allo) | Retro | B-ALL, B-CLL, B-NHL | Baylor | Phase 1 | 40 | NCT02050347 |
CD19 | CD28z | T cells | Retro | B-NHL | Jichi Med. Univ.|Takara | Phase1,2 | 18 | NCT02134262 |
CD19 | CD28z | T cells | Retro | B-NHL | Kite Pharma | Phase1,2 | 124 | NCT02348216 |
CD19 | CD28z | T cells | Retro | B-ALL | Juno | Phase 2 | 90 | NCT02535364 |
CD19 | CD28z | T cells | Retro | B-NHL | Kite Pharma | Phase 2 | 70 | NCT02601313 |
CD19 | CD28z | T cells | Retro | B-ALL | Kite Pharma | Phase1,2 | 75 | NCT02614066 |
CD19 | CD28z | T cells | Retro | B-ALL | Kite Pharma | Phase1,2 | 75 | NCT02625480 |
CD19 | CD28z | T cells | Retro | B-NHL | Xuzhou Med. College | Phase1,2 | 20 | NCT02652910 |
CD19 | CD28z | T cells | Retro | B-ALL | Juno | 500 | NCT02813252 | |
CD19 | CD28z | T cells | Retro | B-ALL, B-NHL | Sheba Med. Center | Phase1,2 | 40 | NCT02772198 |
CD19 | CD28z and 41BBz | T cells | Lenti | B-ALL | AMMS|PKU | Phase 1 | 5 | NCT02186860 |
CD19 | CD28z and 41BBz | T cells | NA | B-ALL, B-CLL, B-NHL | Xuzhou Med. College | Phase1,2 | 20 | NCT02685670 |
CD19 | CD28z and CD28-41BBz | T cells | Retro | B-ALL, B-CLL, B-NHL | Baylor | Phase 1 | 14 | NCT01853631 |
CD19 | CD28z and zeta-only | Tcm-enriched T cells | Lenti | B-NHL | City of Hope|NCI | Phase1,2 | 57 | NCT01318317 |
CD19 | CD28z,EGFRt | T cells | Lenti | B-ALL | Seattle Children's | Phase 1 | 18 | NCT01683279 |
CD19 | CD28z,EGFRt | T cells Tcm or Tn,Tnem | Lenti | B-ALL | City of Hope|NCI | Phase 1 | 48 | NCT02146924 |
CD19 | CD28z,undefined safety switch | T cells | Retro or Lenti | B-ALL, B-CLL, B-NHL | Shenzhen Second People's Hospital | Phase 1 | 36 | NCT02456350 |
CD19 | NA | T cells | NA | B-ALL, B-CLL, B-NHL | Southwest Hospital, China | Phase1,2 | 45 | NCT02349698 |
CD19 | NA | T cells | NA | B-ALL, B-CLL, B-NHL | ICT | 30 | NCT02813837 | |
CD19 | NA | T cells | Lenti | B-ALL, B-CLL, B-NHL | Tongji Univ. Med. | Phase1,2 | 40 | NCT02537977 |
CD19 | NA | T cells | NA | B-CLL | SMMU | Phase1,2 | 20 | NCT02644655 |
CD19 | NA | T cells (allo) | NA | B-ALL | AMMS|Chinese PLAGH | Phase 1 | 10 | NCT02799550 |
CD19 | NA | T cells | NA | B-NHL | Sinobioway Cell Therapy | Phase1,2 | 24 | NCT02728882 |
CD19 | NA | T cells | NA | B-ALL | Sinobioway Cell Therapy | Phase1,2 | 24 | NCT02735291 |
CD19 | NA | T cells | NA | B-NHL | Univ. College, London | Phase 1 | 12 | NCT02431988 |
CD19 | NA | T cells | NA | B-ALL, B-CLL, B-NHL | Beijing Doing Biomed. | Phase 1 | 100 | NCT02546739 |
CD19 | NA | YδT-cells (allo) | NA | B-ALL, B-CLL, B-NHL | Beijing Doing Biomed. | Phase 1 | 48 | NCT02656147 |
CD19 | NA | T cells | Retro | B-ALL, B-CLL, B-NHL | NCI|NIHCC | Phase 1 | 64 | NCT02659943 |
CD19 | NA | T cells | NA | B-ALL | Guangdong General Hospital|CAS | Phase 1 | 30 | NCT02822326 |
CD19 | NA | T cells | NA | B-ALL, B-NHL | Univ. College, London | Phase 1 | 18 | NCT02443831 |
CD19 | NA | T cells | NA | B-CLL | iCarTAB Xuzhou Med. | Phase1,2 | 50 | NCT02782351 |
CD19 | NA | T cells | NA | B-NHL | PKU|Marino | Phase 1 | 20 | NCT02842138 |
CD19 | NA | T cells | NA | B-ALL, B-CLL, B-NHL | PersonGen | Phase1,2 | 10 | NCT02851589 |
CD19 | NA | T cells | NA | B-ALL, B-CLL, B-NHL | PersonGen | Phase1,2 | 10 | NCT02819583 |
CD19 | zeta-only | T cells | Retro | B-NHL | Christie NHS Foundation | Phase 1 | 24 | NCT01493453 |
CD19, CD20 | NA | T cells | NA | B-NHL | Southwest Hospital, China | Phase1,2 | 40 | NCT02737085 |
CD19, Mesothelin | 41BBz | T cells | Lenti | Pancreatic Cancer | UPenn\UCSF | Phase 1 | 12 | NCT02465983 |
CD20 | NA | T cells | Virus | B-ALL, B-CLL, B-NHL | Southwest Hospital, China | Phase1,2 | 45 | NCT02710149 |
CD22 | 41BBz | T cells | Lenti | B-ALL, B-NHL | NCI|NIHCC | Phase 1 | 57 | NCT02315612 |
CD22 | 41BBz | T cells | Lenti | B-ALL | UPenn | 15 | NCT02588456 | |
CD22 | 41BBz | T cells | Lenti | B-ALL | UPenn|CHOP | Phase 1 | 15 | NCT02650414 |
CD22 | 41BBz | T cells | Retro | B-NHL | Xuzhou Med. | Phase 1 | 20 | NCT02721407 |
CD22 | NA | T cells | Virus | B-ALL, B-CLL, B-NHL | iCarTAB|Xuzhou Med. | Phase1,2 | 10 | NCT02794961 |
CD30 | CD27z,iCasp9 | T cells | Lenti | HL, B-NHL | PKU|UF | Phase1,2 | 20 | NCT02274584 |
CD30 | CD28z | T cells | Virus | HL, B-NHL | UNC Lineberger|Baylor | Phase 1 | 18 | NCT01316146 |
CD30 | CD28z | T cells | Virus | HL, B-NHL | UNC Lineberger | Phase 1 | 18 | NCT02663297 |
CD30 | CD28z | T cells | Virus | HL, B-NHL | UNC Lineberger | Phase1,2 | 31 | NCT02690545 |
CD30 | NA | T cells | NA | HL, B-NHL | Chinese PLAGH | Phase1,2 | 30 | NCT02259556 |
CD33 | 41BBz and zeta-only | T cells | Retro | AML | Chinese | Phase1,2 | 10 | NCT01864902 |
CD33 | 41BBz and zeta-only | T cells | Retro | AML | AMMS|Chinese PLAGH | Phase 1 | 12 | NCT02799680 |
CD70 | NA | T cells | Retro | CD70+ cancers | NCI|NIHCC | Phase1,2 | 113 | NCT02830724 |
CD123 | 41BBz | T cells | RNA (electro) | AML | UPenn | Phase 0 | 7 | NCT02623582 |
CD123 | CD28z,EGFRt | T cells | Lenti | AML | City of Hope NCI | Phase 1 | 30 | NCT02159495 |
CD133 | 41BBz and zeta-only | T cells | Retro | AML, B-ALL, various solid tumors | Chinese PLAGH | Phase 1 | 20 | NCT02541370 |
CD138 | 41BBz and zeta-only | T cells | Retro | MM | Chinese PLAGH | Phase1,2 | 10 | NCT01886976 |
CD171 | CD28-41BBz,EGFRt and 41BBz,EGFRt | T cells 1:1 CD4+ and CD8+ | Lenti | Neuroblastoma | Seattle Children's | Phase 1 | 80 | NCT02311621 |
CEA | CD28z | T cells | NA | Various solid tumors | Roger Williams | Phase 2 | 48 | NCT01723306 |
CEA | NA | T cells | NA | Various solid tumors | Southwest Hospital, China | Phase 1 | 75 | NCT02349724 |
CEA | zeta-only | T cells | Retro | Various solid tumors | Cancer Research UK | Phase 1 | 14 | NCT01212887 |
EGFR | 41BBz and zeta-only | T cells | Lenti | EGFR+ Solid Tumors | Chinese PLAGH | Phase1,2 | 60 | NCT01869166 |
EGFRvIII | 41BBz | T cells | Lenti | Glioma | UPenn|UCSF | 12 | NCT02209376 | |
EGFRvIII | 41BBz | T cells | Lenti | Glioblastoma | UPenn | 8 | NCT02666248 | |
EGFRvIII | CD28-41BBz | T cells | Retro | Glioma | NCI|NIHCC | Phase1,2 | 18 | NCT01454596 |
EGFRvIII | NA | T cells | Lenti | Glioma | RenJi Hospital | Phase 1 | 10 | NCT02331693 |
EGFRvIII | NA | T cells | Retro | Glioblastoma | Duke Univ. | Phase 1 | 48 | NCT02664363 |
EGFRvIII | NA,EGFRt | T cells | Lenti | Glioblastoma | Beijing Sanbo Marino | Phase 1 | 20 | NCT02844062 |
EPCAM | NA | T cells | NA | Stomach Neoplasms | Sinobioway | Phase1,2 | 19 | NCT02725125 |
EPCAM | NA | T cells | NA | Liver Neoplasms | Sinobioway | Phase1,2 | 25 | NCT02729493 |
EPHA2 | NA | T cells | NA | Glioma | Fuda, Guangzhou | Phase1,2 | 60 | NCT02575261 |
ErbB dimers | CD28z,4aβ | T cells | Retro | Head and Neck Cancer | King's College | Phase 1 | 30 | NCT01818323 |
FAP | CD28z | CD8+ T cells | Retro | Mesothelioma | Univ. of Zurich | Phase 1 | 6 | NCT01722149 |
GD2 | CD28-41BB-CD27z,iCasp9 | T cells | Lenti | Neuroblastoma | Zhujiang Hospital | Phase 2 | 30 | NCT02765243 |
GD2 | CD28- | T cells | Retro | Neuroblastoma | Baylor|NCI | Phase 1 | 11 | NCT01822652 |
GD2 | CD28-OX40z,iCasp9 | NK T cells | Retro | Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma | NCI|NIHCC | Phase 1 | 72 | NCT02107963 |
GD2 | CD28-OX40z,iCasp9 | VZV T cells | Retro | Sarcomas | Baylor|NCI | Phase 1 | 26 | NCT01953900 |
GD2 | CD28-OX40z,iCasp9 | NK T cells | Retro | Neuroblastoma | Baylor | Phase 1 | 18 | NCT02439788 |
GD2 | CD28z | T cells | Virus | Neuroblastoma | Cancer Research UK | Phase 1 | 27 | NCT02761915 |
GD2 | NA | triVirus-CTLs (allo) | Retro | Neuroblastoma | Children's Mercy, KC | Phase 1 | 5 | NCT01460901 |
GPC3 | 41BBz | T cells | Virus | Hepatocellular Carcinoma | Shanghai GeneChem | Phase1,2 | 30 | NCT02715362 |
GPC3 | CD28-41BBz | T cells | Virus | Hepatocellular Carcinoma | RenJi Hospital | Phase 1 | 20 | NCT02395250 |
GPC3 | NA | T cells | NA | Hepatocellular Carcinoma | Fuda, Guangzhou | Phase1,2 | 60 | NCT02723942 |
HER2 | 41BBz and zeta-only | T cells | Virus | HER-2+ Solid Tumors | Chinese PLAGH | Phase1,2 | 10 | NCT01935843 |
HER2 | CD28z | T cells | Virus | Sarcoma | Baylor | Phase 1 | 36 | NCT00902044 |
HER2 | CD28z | CMV T cells | Virus | Glioblastoma | Baylor | Phase 1 | 16 | NCT01109095 |
HER2 | CD28z | T cells | Retro | Breast Cancer | Fuda, Guangzhou | Phase1,2 | 60 | NCT02547961 |
HER2 | CD28z | T cells | Virus | Glioblastoma | Baylor | Phase 1 | 14 | NCT02442297 |
HER2 | CD28z,TGFβDN | EBV T cells | Retro | HER2+ Malignancies | Baylor | Phase 1 | 19 | NCT00889954 |
HER2 | NA | T cells | NA | Various solid tumors | Southwest Hospital, China | Phase1,2 | 60 | NCT02713984 |
IL-1-RAP | NA | NA | NA | CML | Univ. Hospital of Besancon | 40 | NCT02842320 | |
IL-13R | 41BBz,CD19t | T cells Tcm-enriched | Lenti | Glioma | City of Hope|NCI | Phase 1 | 75 | NCT02208362 |
Kappa | CD28z | T cells | Retro | B-CLL, B-NHL | Baylor | Phase 1 | 54 | NCT00881920 |
LeY | CD28z | T cells | Retro | MM, AML, MDS | Peter MacCallum | Phase 1 | 6 | NCT01716364 |
Mesothelin | 41BBz | T cells | RNA (electro) | Mesothelioma | Upenn | Phase 1 | 18 | NCT01355965 |
Mesothelin | 41BBz | T cells | Lenti | Various solid tumors | UPenn | Phase 1 | 21 | NCT02159716 |
Mesothelin | 41BBz | T cells | Lenti | Various solid tumors | UPenn | 50 | NCT02388828 | |
Mesothelin | 41BBz | T cells | Retro | Various Mesothelin+ Tumors | Chinese PLAGH | Phase 1 | 20 | NCT02580747 |
Mesothelin | 41BBz | T cells | Virus | Pancreatic Cancer | Shanghai GeneChem | Phase 1 | 30 | NCT02706782 |
Mesothelin | CD28-41BBz | T cells | Retro | Various solid tumors | NCI|NIHCC | Phase1,2 | 15 | NCT01583686 |
Mesothelin | CD28z-iCasp9 | T cells | Virus | Mesothelioma, Lung and Breast Cancers | MSKCC | Phase 1 | 24 | NCT02414269 |
Mesothelin | NA | T cells | Virus | Breast Cancer | MSKCC | Phase 1 | 24 | NCT02792114 |
MUC1 | CD28-41BBz | T cells | Virus | Various solid tumors | PersonGen | Phase1,2 | 20 | NCT02587689 |
MUC1 | CD28-41BBz | T cells | Virus | Glioma, colorectal, gastric | PersonGen | Phase1,2 | 20 | NCT02617134 |
MUC1 | NA | pNK cells | NA | Various solid tumors | PersonGen | Phase1,2 | 10 | NCT02839954 |
MUC16 | CD28zfIL-12 | T cells | NA | Ovarian Cancer | MSKCC | Phase 1 | 30 | NCT02498912 |
NKG2D | NA | T cells | Virus | AML, Myelodysplastic Syndrome, MM | Celdara Med. | Phase 1 | 21 | NCT02203825 |
PSCA | zeta-only, iCD40/MyD88 | T cells | Retro | Pancreatic Cancer | Bellicum | Phase 1 | 30 | NCT02744287 |
PSMA | CD28z | T cells | Retro | Prostate Cancer | Roger Williams | Phase 1 | 18 | NCT00664196 |
PSMA | CD28z | T cells | Virus | Prostate Cancer | MSKCC | Phase 1 | 18 | NCT01140373 |
ROR1 | 41BBz | T cells | NA | B-ALL, B-CLL, B-NHL, Various solid tumors | FHCRC|NCI | Phase 1 | 60 | NCT02706392 |
Unless specified cells are autologous patient-derived cells.
”Virus” indicates that the trial description mentions introducing the CAR by viral transduction but does not specify the kind of virus used.
Trials with recruitment listed as “Completed,” “Active but not recruiting,” “Terminated” or “Suspended” on clinicaltrails.gov are italicized. Trials were obtained by bulk data download from clinicaltrials.gov on August 1st 2016.